We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .
Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan.
PURPOSE Clinical studies have suggested that venlafaxine induces a higher remission rate than paroxetine . However , very few studies have evaluated relapse episodes over treatment periods longer than a few weeks , and the cut-off score of 7 on the Hamilton Rating Scale for Depression ( HRSD ) often used to define remission is too high . This score is associated with the high rates of social function impairment . We report on a single centre , open-label , prospect i ve 24-week study to investigate the comparative efficacy of acute treatments with venlafaxine and paroxetine , using different definitions of response and remission rates . METHODS Out patients satisfying DSM-IV criteria for major depression with a baseline HRSD17 score of at least 16 were eligible . Following baseline evaluations , the patients were assigned to receive venlafaxine 75 - 225 mg/day with the mean dosage 141.35 + /- 26.98 ( SD ) mg/day ( n = 78 ) , or paroxetine 20 mg/day ( n = 92 ) for 24 weeks . Efficacy was assessed using the mean change in HRSD(17 ) score from baseline , the response rate and the remission rates based on different criteria for remission ( HRSD(17 ) score < or = 7 or 5 ) . RESULTS One hundred and seventy patients were evaluated for efficacy ; 78 treated with venlafaxine and 92 with paroxetine .  Over the treatment period , venlafaxine was comparable with paroxetine on most outcome measures , whereas paroxetine produced significantly higher remission rates at weeks 4 , 8 , 16 , 20 and 24 weeks when the lower cutoff of 5 was used . CONCLUSIONS Venlafaxine treatment was similar to paroxetine according to the typical efficacy measures for treating out patients with major depression . However , based on the stricter remission criterion , paroxetine might be superior to venlafaxine
We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .